Tamoxifen Better at 10 Years than 5 - 8 News NOW

Tamoxifen Better at 10 Years than 5

Posted: Updated:

A new study on the effectiveness of the breast cancer drug Tamoxifen has found that patients can do better by taking the drug for ten years, rather than the current standard of five.

The study made quite a stir in the cancer treatment world in December when it was presented at the San Antonio Breast Cancer Symposium. The international study involved 6,846 breast cancer survivors and found that those who took tamoxifen for ten years had a lower rate of returning breast cancer, than those who took the drug for five years and then stopped.  The death rate was also improved.

All the study participants had estrogen-receptor positive cases of breast cancer. At the Comprehensive Cancer Centers of Nevada, breast cancer specialist Dr. Mary Ann Allison has been using Tamoxifen on patients for many years. The new findings show an exciting improvement. She told 8 News Now, "The take home for most women who are on Tamoxifen, when they approach the five year point, they should really have a serious conversation about the pros and cons of continuing. Everybody is different; all tumors are different, but at that point and time you need to be looking at taking Tamoxifen for ten years versus five years."

For the group taking Tamoxifen for ten years, the risk of their cancer returning was just over 21-percent. For the group which took tamoxifen for just five years, and stopped, the risk of recurrence was 25-percent.

The death rate was also reduced in the 10 year group. As for side effects, a slight increase in the risk for endometrial cancer was seen, but it didn't affect the death rate and no increase in stroke risk was seen.

Here is a link to another article on the ten-year study of Tamoxifen:
http://www.cancer.org/cancer/news/news/study-ten-years-of-tamoxifen-better-than-five

And a dissenting viewpoint:
http://www.clinicaloncology.com/ViewArticle.aspx?d=Solid%2BTumors&d_id=148&i=January+2013&i_id=926&a_id=22432



  • Paula's Health NotesLas Vegas Health NewsMore>>

  • Training the body to fight melanoma

    Training the body to fight melanoma

    Monday, September 1 2014 1:39 PM EDT2014-09-01 17:39:25 GMT

    The numbers are staggering. One person dies of melanoma every hour and one in fifty men and women will be diagnosed with melanoma at some point in their lifetime. Now a new experimental therapy is training the body's immune system to fight the disease.

    More>>

    The numbers are staggering. One person dies of melanoma every hour and one in fifty men and women will be diagnosed with melanoma at some point in their lifetime. Now a new experimental therapy is training the body's immune system to fight the disease.

    More>>
  • New procedure to help Lipedema

    New procedure to help Lipedema

    Friday, August 22 2014 3:55 PM EDT2014-08-22 19:55:58 GMT
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>
  • Brain surgery through the nose

    Brain surgery through the nose

    Monday, September 1 2014 1:45 PM EDT2014-09-01 17:45:33 GMT
    Removing a brain tumor can be tricky for surgeons and painful for patients. Now there's a new way to take out these lesions as surgeons are using the nose as a pathway to the brain.More>>
    Removing a brain tumor can be tricky for surgeons and painful for patients. Now there's a new way to take out these lesions as surgeons are using the nose as a pathway to the brain.More>>
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KLAS. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.